Crystallization a 1alpha-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3
US8519169B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2012 |
| Grant date | Aug 27, 2013 |
| Priority date | — |
| Expiry date | Aug 17, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2602/24
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A method of purifying 1α-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 to obtain 1α-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 in crystalline form. The method includes the steps of preparing a solvent of either ethyl formate or a mixture of ethyl formate and hexane, dissolving a product containing 1α-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 to be purified in the solvent, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of 1α-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 crystals, and recovering the 1α-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 crystals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.